MX2019009615A - Polipeptidos dise?ados de fenilalanina amonio liasa. - Google Patents

Polipeptidos dise?ados de fenilalanina amonio liasa.

Info

Publication number
MX2019009615A
MX2019009615A MX2019009615A MX2019009615A MX2019009615A MX 2019009615 A MX2019009615 A MX 2019009615A MX 2019009615 A MX2019009615 A MX 2019009615A MX 2019009615 A MX2019009615 A MX 2019009615A MX 2019009615 A MX2019009615 A MX 2019009615A
Authority
MX
Mexico
Prior art keywords
polypeptides
engineered
pal
ammonia lyase
phenylalanine ammonia
Prior art date
Application number
MX2019009615A
Other languages
English (en)
Inventor
W Huisman Gjalt
DELLAS Nikki
Alvizo Oscar
Chng Chinping
Casey HALLOWS William
J Agard Nicholas
Joseph NICOLS John
Original Assignee
Codexis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Codexis Inc filed Critical Codexis Inc
Publication of MX2019009615A publication Critical patent/MX2019009615A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Abstract

La presente invencion proporciona polipeptidos disenados de fenilalanina amonio liasa (PAL) y composiciones de los mismos, asi como polinucleotidos que codifican a los polipéptidos disenados de fenilalanina amonio liasa (PAL); en algunas modalidades, los polipeptidos disenados de PAL son optimizados para proporcionar una mejor actividad catalitica, asi como una sensibilidad reducida a la proteolisis y con mayor tolerancia al almacenamiento a temperaturas elevadas; en algunas modalidades, los polipeptidos disenados de PAL contienen pocos residuos de fenilalanina que los polipeptidos de PAL tipo salvaje; la presente invencion tambien proporciona metodos para el uso de composiciones que comprenden los polipeptidos de PAL disenados con fines terapeuticos e industriales.
MX2019009615A 2017-02-13 2018-02-12 Polipeptidos dise?ados de fenilalanina amonio liasa. MX2019009615A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762458232P 2017-02-13 2017-02-13
US201762565555P 2017-09-29 2017-09-29
PCT/US2018/017773 WO2018148633A1 (en) 2017-02-13 2018-02-12 Engineered phenylalanine ammonia lyase polypeptides

Publications (1)

Publication Number Publication Date
MX2019009615A true MX2019009615A (es) 2019-10-14

Family

ID=63106144

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009615A MX2019009615A (es) 2017-02-13 2018-02-12 Polipeptidos dise?ados de fenilalanina amonio liasa.

Country Status (15)

Country Link
US (4) US10995329B2 (es)
EP (1) EP3579867A4 (es)
JP (2) JP2020505942A (es)
KR (1) KR102573324B1 (es)
CN (1) CN110573175A (es)
AU (1) AU2018217495B2 (es)
BR (1) BR112019016634A2 (es)
CA (1) CA3051262A1 (es)
IL (1) IL268226A (es)
MX (1) MX2019009615A (es)
MY (1) MY196740A (es)
NZ (1) NZ755628A (es)
PH (1) PH12019501705A1 (es)
SG (1) SG11201906880VA (es)
WO (1) WO2018148633A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241132A1 (en) 2018-06-12 2019-12-19 Codexis, Inc. Engineered tyrosine ammonia lyase
CN112355034B (zh) 2020-11-17 2021-08-06 同济大学 基于水热钙离子调配的有机固体废弃物无害化预处理方法
CN115518691B (zh) * 2022-10-14 2023-11-21 天津大学 一种具有类漆酶活性的人工酶及制备方法和应用

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK75593D0 (es) 1993-06-25 1993-06-25 Novo Nordisk As
US5928905A (en) 1995-04-18 1999-07-27 Glaxo Group Limited End-complementary polymerase reaction
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6309883B1 (en) 1994-02-17 2001-10-30 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6995017B1 (en) 1994-02-17 2006-02-07 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US20060257890A1 (en) 1996-05-20 2006-11-16 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US6406855B1 (en) 1994-02-17 2002-06-18 Maxygen, Inc. Methods and compositions for polypeptide engineering
US6395547B1 (en) 1994-02-17 2002-05-28 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
CA2191718A1 (en) 1994-06-03 1995-12-14 Randy M. Berka Phosphonyldipeptides useful in the treatment of cardiovascular diseases
ATE294871T1 (de) 1994-06-30 2005-05-15 Novozymes Biotech Inc Nicht-toxisches, nicht-toxigenes, nicht- pathogenes fusarium expressionssystem und darin zu verwendende promotoren und terminatoren
FI104465B (fi) 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
US6096548A (en) 1996-03-25 2000-08-01 Maxygen, Inc. Method for directing evolution of a virus
US6506602B1 (en) 1996-03-25 2003-01-14 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US7148054B2 (en) 1997-01-17 2006-12-12 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
WO1998031837A1 (en) 1997-01-17 1998-07-23 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
WO1998031816A1 (en) 1997-01-17 1998-07-23 Regents Of The University Of Minnesota Dna molecules and protein displaying improved triazine compound degrading ability
US6537746B2 (en) 1997-12-08 2003-03-25 Maxygen, Inc. Method for creating polynucleotide and polypeptide sequences
EP1068351A2 (en) 1998-04-02 2001-01-17 Tellus Genetic Resources, Inc. A method for obtaining a plant with a genetic lesion in a gene sequence
EP1073670A1 (en) 1998-05-01 2001-02-07 Maxygen, Inc. Optimization of pest resistance genes using dna shuffling
WO1999065927A2 (en) 1998-06-17 1999-12-23 Maxygen, Inc. Method for producing polynucleotides with desired properties
US6365408B1 (en) 1998-06-19 2002-04-02 Maxygen, Inc. Methods of evolving a polynucleotides by mutagenesis and recombination
CA2332615A1 (en) 1998-08-12 2000-02-24 Maxygen Inc. Dna shuffling of monooxygenase genes for production of industrial chemicals
WO2000020573A2 (en) 1998-10-07 2000-04-13 Maxygen, Inc. Dna shuffling to produce nucleic acids for mycotoxin detoxification
WO2000028018A1 (en) 1998-11-10 2000-05-18 Maxygen, Inc. Modified adp-glucose pyrophosphorylase for improvement and optimization of plant phenotypes
JP4221100B2 (ja) 1999-01-13 2009-02-12 エルピーダメモリ株式会社 半導体装置
US6376246B1 (en) 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US6436675B1 (en) 1999-09-28 2002-08-20 Maxygen, Inc. Use of codon-varied oligonucleotide synthesis for synthetic shuffling
US6917882B2 (en) 1999-01-19 2005-07-12 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6368861B1 (en) 1999-01-19 2002-04-09 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7702464B1 (en) 2001-08-21 2010-04-20 Maxygen, Inc. Method and apparatus for codon determining
IL137868A0 (en) 1999-01-19 2001-10-31 Maxygen Inc Oligonucleotide mediated nucleic acid recombination
US8457903B1 (en) 1999-01-19 2013-06-04 Codexis Mayflower Holdings, Llc Method and/or apparatus for determining codons
US7873477B1 (en) 2001-08-21 2011-01-18 Codexis Mayflower Holdings, Llc Method and system using systematically varied data libraries
US20070065838A1 (en) 1999-01-19 2007-03-22 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
US7024312B1 (en) 1999-01-19 2006-04-04 Maxygen, Inc. Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US6961664B2 (en) 1999-01-19 2005-11-01 Maxygen Methods of populating data structures for use in evolutionary simulations
KR20010102069A (ko) 1999-02-11 2001-11-15 추후제출 고효율 질량 분석
AU3719500A (en) 1999-03-05 2000-09-21 Maxygen, Inc. Recombination of insertion modified nucleic acids
US6703240B1 (en) 1999-04-13 2004-03-09 Maxygar, Inc. Modified starch metabolism enzymes and encoding genes for improvement and optimization of plant phenotypes
US7430477B2 (en) 1999-10-12 2008-09-30 Maxygen, Inc. Methods of populating data structures for use in evolutionary simulations
US6519065B1 (en) 1999-11-05 2003-02-11 Jds Fitel Inc. Chromatic dispersion compensation device
US6686515B1 (en) 1999-11-23 2004-02-03 Maxygen, Inc. Homologous recombination in plants
CA2396320A1 (en) 2000-01-11 2001-07-19 Maxygen, Inc. Integrated systems and methods for diversity generation and screening
AU4964101A (en) 2000-03-30 2001-10-15 Maxygen Inc In silico cross-over site selection
WO2001075087A2 (en) 2000-04-03 2001-10-11 Maxygen, Inc. Subtilisin variants
US7747391B2 (en) 2002-03-01 2010-06-29 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
US20050084907A1 (en) 2002-03-01 2005-04-21 Maxygen, Inc. Methods, systems, and software for identifying functional biomolecules
SI2315145T1 (sl) 2002-03-01 2016-03-31 Codexis Mayflower Holdings, Llc Postopki, sistemi in programska oprema za identificiranje funkcionalnih biomolekul
WO2003078583A2 (en) 2002-03-09 2003-09-25 Maxygen, Inc. Optimization of crossover points for directed evolution
US8003356B2 (en) 2004-04-20 2011-08-23 E. I. Du Pont De Nemours And Company Methods for the preparation of para-hydroxycinnamic acid and cinnamic acid at alkaline pH
EP2886658A1 (en) 2005-03-10 2015-06-24 BASF Enzymes LLC Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US8768871B2 (en) 2008-02-12 2014-07-01 Codexis, Inc. Method of generating an optimized, diverse population of variants
US8504498B2 (en) 2008-02-12 2013-08-06 Codexis, Inc. Method of generating an optimized, diverse population of variants
US8383346B2 (en) 2008-06-13 2013-02-26 Codexis, Inc. Combined automated parallel synthesis of polynucleotide variants
US20090312196A1 (en) 2008-06-13 2009-12-17 Codexis, Inc. Method of synthesizing polynucleotide variants
HUE029228T2 (en) 2008-06-13 2017-02-28 Codexis Inc A method for the synthesis of polynucleotide variants
PT3025728T (pt) 2010-02-04 2018-11-05 Biomarin Pharm Inc Método para purificar variantes procarióticas de fenilalanina amónia-liase
CA2815341A1 (en) 2010-11-05 2012-05-10 Basf Plant Science Company Gmbh Methods for increasing yield and fine chemical production in plants
WO2012122333A1 (en) 2011-03-08 2012-09-13 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Microbial conversion of glucose to styrene and its derivatives
WO2012178126A1 (en) 2011-06-23 2012-12-27 Phytogene, Inc. Enzymatic system for monomer synthesis
HUE042817T2 (hu) 2011-06-28 2019-07-29 Codexis Inc Fehérjevariánsok elõállítása régiókeveréssel
US20150050658A1 (en) 2012-03-15 2015-02-19 Codexix, Inc. Gene shuffling methods
KR102490720B1 (ko) 2013-01-31 2023-01-27 코덱시스, 인코포레이티드 상호작용 성분을 이용하여 생체분자를 확인하기 위한 방법, 시스템, 및 소프트웨어
PL2986722T3 (pl) * 2013-04-18 2019-10-31 Codexis Inc Skonstruowane polipeptydy amoniakoliazy fenyloalaniny
DK3049979T3 (da) 2013-09-27 2020-02-17 Codexis Inc Struktur-baseret prædiktiv konstruktion
DK3418929T3 (da) 2013-09-27 2021-02-01 Codexis Inc Automatiseret screening af enzymvarianter
AU2014348683B2 (en) * 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes

Also Published As

Publication number Publication date
US20210222145A1 (en) 2021-07-22
IL268226A (en) 2019-09-26
EP3579867A4 (en) 2021-03-10
JP2022103296A (ja) 2022-07-07
KR20190117577A (ko) 2019-10-16
CN110573175A (zh) 2019-12-13
US10995329B2 (en) 2021-05-04
WO2018148633A1 (en) 2018-08-16
PH12019501705A1 (en) 2020-07-06
AU2018217495B2 (en) 2021-03-04
KR102573324B1 (ko) 2023-08-30
US20230295598A1 (en) 2023-09-21
JP2020505942A (ja) 2020-02-27
AU2018217495A1 (en) 2019-08-08
US20230295599A1 (en) 2023-09-21
SG11201906880VA (en) 2019-08-27
BR112019016634A2 (pt) 2020-04-07
EP3579867A1 (en) 2019-12-18
NZ755628A (en) 2023-09-29
MY196740A (en) 2023-05-03
CA3051262A1 (en) 2018-08-16
US20180230448A1 (en) 2018-08-16

Similar Documents

Publication Publication Date Title
PH12015502412A1 (en) Engineered phenylalanine ammonia lyase polypeptides
MX2016011752A (es) Variantes de hppd y metodos de uso.
PH12019501705A1 (en) Engineered phenylalanine ammonia lyase polypeptides
MX2016011745A (es) Variantes de hppd y metodos de uso.
MX2017005481A (es) Variantes de interferon a2b.
UA117218C2 (uk) Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
MX2019008803A (es) Anticuerpos contra el inhibidor del activador de plasminogeno tipo 1 (pai-1) y usos de los mismos.
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
MX371442B (es) VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB.
TN2012000372A1 (en) Fibronectin based scaffold domain proteins that bind il-23
PH12014502669B1 (en) Therapeutic agent or prophylactic agent for dementia
MX342920B (es) Metodo para purificar polipeptidos o inmunoconjugados activos.
MX2013007904A (es) Anticuerpos anti-il-12/il-23 y usos de los mismos.
EA200901430A1 (ru) Варианты фермента аспарагиназы и их применение
MX2019013289A (es) Variantes de ligasa modificadas geneticamente.
MX2014006399A (es) Uso de inhibidores de peptidos con celulas permeables de la via para transduccion de señal de jnk para el tratamiento de la queratoconjuntivitis seca.
MX2021000322A (es) Enzimas de variante fosfopentomutasa modificada geneticamente.
MX2018003044A (es) Variantes de hppd y metodos de uso.
MX2013003236A (es) Variantes de polipeptidos que tienen actividad potenciadora celulolitica y polinucleotidos que codifican a los mismos.
PH12016500320A1 (en) Cyclosporin analogues for preventing or treating hepatitis c
PH12018501114A1 (en) Polypeptides inhibiting cd40l
GB2517354A (en) Hydrochloride salt of peptide and its use in combination with other peptides for immunotherapy
MX2018015534A (es) Beta-glucosidasas dise?adas y metodos de glucosilacion.
IN2014DE00902A (es)
WO2013192238A3 (en) Compositions and methods for treatment of diabetes